Core Insights - CERo Therapeutics Holdings, Inc. announced a key clinical update regarding its CertainT-1 trial for patients with acute myeloid leukemia (AML), reporting cell expansion with no treatment-related adverse events observed to date [1][3] - The company has amended the CertainT-1 trial to include advanced myelodysplastic syndrome (MDS) and myelofibrosis (MF) as additional cohorts [2][3] - A conference call is scheduled for January 7, 2026, to discuss the trial's progress and the company's future strategy [5] Clinical Trial Update - The CertainT-1 trial has completed the dose-limiting toxicity observation period for the first cohort, with investigators noting a 61-day platelet transfusion-free interval after treatment with CER-1236, surpassing the 8-week benchmark commonly referenced in clinical studies [1][3] - The trial is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with AML, including those who are relapsed/refractory or newly diagnosed with TP53 mutated MDS/AML [3][4] - Primary outcome measures include the incidence of adverse events, dose-limited toxicities, and overall response rate, while secondary measures focus on pharmacokinetics [3] Strategic Expansion - The inclusion of MDS and MF in the trial is seen as a significant milestone, with the company emphasizing the importance of careful dose escalation and systematic safety data collection [4] - The CEO expressed gratitude to trial participants and shareholders, highlighting the company's commitment to advancing its clinical programs [4] Company Overview - CERo is focused on developing next-generation engineered T cell therapeutics for cancer treatment, utilizing a novel cellular immunotherapy platform that integrates innate and adaptive immunity [7][8] - The company's lead product candidate, CER-1236, is currently in clinical trials for hematologic malignancies, aiming to offer advantages over existing CAR-T therapies [8]

As filed with the Securities and Exchange Commission on June 5, 2024 Registration No. 333-279156 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CERO THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2836 81-4182129 (I.R.S. Employer Identific ...